TY - JOUR
T1 - Burden of Valvular Heart Diseases in Hispanic/Latino Individuals in the United States
T2 - The Echocardiographic Study of Latinos
AU - Rubin, Jonathan
AU - Aggarwal, Shivani R.
AU - Swett, Katrina R.
AU - Kirtane, Ajay J.
AU - Kodali, Susheel K.
AU - Nazif, Tamim M.
AU - Pu, Min
AU - Dadhania, R.
AU - Kaplan, Robert C.
AU - Rodriguez, Carlos J.
N1 - Funding Information:
Grant Support: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was performed as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (grant no. N01-HC65233), University of Miami (grant no. N01-HC65234), Albert Einstein College of Medicine (grant no. N01-HC65235), Northwestern University (grant no. N01-HC65236), and San Diego State University (grant no. N01-HC65237). The following institutes/centers/offices contribute to HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, and Office of Dietary Supplements, National Institutes of Health. The Echocardiographic Study of Latinos was supported by grant R01 HL104199 (C.J.R.).Potential Competing Interests: Dr Kirtane has received grants from Medtronic, Abbott Vascular, Boston Scientific, Abiomed, CathWorks, Siemens, Philips, ReCor Medical, and Spectranetics. Dr Kodali is a board member of Abbott Vascular; he has received consultancy fees from Merrill Life Sciences and Claret Medical, payment for development of educational presentations from Edwards Lifesciences, and travel/accommodations/meeting expenses (unrelated to activities listed) from Edwards Lifesciences, Medtronic, and Abbott Vascular; he owns stock/stock options in Dura Biotech, BioTrace Medical, and Thubrikar Aortic Valve. Dr Nazif has received consultancy fees from Edwards Lifesciences and Medtronic. Dr Kaplan has received grants from the National Institutes of Health. Dr Rodriguez has received grants from the National Heart, Lung, and Blood Institute. The other authors report no competing interests. Grant Support: The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) was performed as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (grant no. N01-HC65233), University of Miami (grant no. N01-HC65234), Albert Einstein College of Medicine (grant no. N01-HC65235), Northwestern University (grant no. N01-HC65236), and San Diego State University (grant no. N01-HC65237). The following institutes/centers/offices contribute to HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, and Office of Dietary Supplements, National Institutes of Health. The Echocardiographic Study of Latinos was supported by grant R01 HL104199 (C.J.R.). Potential Competing Interests: Dr Kirtane has received grants from Medtronic, Abbott Vascular, Boston Scientific, Abiomed, CathWorks, Siemens, Philips, ReCor Medical, and Spectranetics. Dr Kodali is a board member of Abbott Vascular; he has received consultancy fees from Merrill Life Sciences and Claret Medical, payment for development of educational presentations from Edwards Lifesciences, and travel/accommodations/meeting expenses (unrelated to activities listed) from Edwards Lifesciences, Medtronic, and Abbott Vascular; he owns stock/stock options in Dura Biotech, BioTrace Medical, and Thubrikar Aortic Valve. Dr Nazif has received consultancy fees from Edwards Lifesciences and Medtronic. Dr Kaplan has received grants from the National Institutes of Health. Dr Rodriguez has received grants from the National Heart, Lung, and Blood Institute. The other authors report no competing interests.
Publisher Copyright:
© 2019
PY - 2019/8
Y1 - 2019/8
N2 - Objective: To explore the burden and clinical correlates of valvular heart disease in Hispanics/Latinos in the United States. Patients and Methods: A total of 1818 individuals from the population-based study of Latinos/Hispanics from 4 US metropolitan areas (Bronx, New York; Chicago, Illinois; San Diego, California; and Miami, Florida) underwent a comprehensive clinical and echocardiographic examination from October 1, 2011, through June 24, 2014. Logistic regression analysis was used to examine the associations of clinical and sociodemographic variables with valvular lesions. Results: The mean age was 55.2±0.2 years; 57.4% were female. The prevalence of any valvular heart disease (AVHD) was 3.1%, with no considerable differences across sex, and a higher prevalence with increasing age. The proportion of US-born vs foreign-born individuals was similar in those with vs without AVHD (P=.31). The weighted prevalence of AVHD was highest in Central Americans (8.4%) and lowest in Mexicans (1.2%). Regurgitant lesions of moderate or greater severity were present in 2.4% of the population and stenotic lesions of moderate or greater severity in 0.2%. Compared with those without AVHD, individuals with AVHD were more likely to have health insurance coverage (59.6% vs 79.2%; P=.007) but similar income (P=.06) and educational status (P=.46). Univariate regression models revealed that regurgitant lesions were associated with lower body mass index whereas stenotic lesions were associated with higher body mass index. Conclusion: Our data provide the first population-based estimates of the prevalence of valvular heart disease in Hispanic/Latinos. Valvular heart disease is fairly common in the Hispanic/Latino population and may constitute an important public health problem.
AB - Objective: To explore the burden and clinical correlates of valvular heart disease in Hispanics/Latinos in the United States. Patients and Methods: A total of 1818 individuals from the population-based study of Latinos/Hispanics from 4 US metropolitan areas (Bronx, New York; Chicago, Illinois; San Diego, California; and Miami, Florida) underwent a comprehensive clinical and echocardiographic examination from October 1, 2011, through June 24, 2014. Logistic regression analysis was used to examine the associations of clinical and sociodemographic variables with valvular lesions. Results: The mean age was 55.2±0.2 years; 57.4% were female. The prevalence of any valvular heart disease (AVHD) was 3.1%, with no considerable differences across sex, and a higher prevalence with increasing age. The proportion of US-born vs foreign-born individuals was similar in those with vs without AVHD (P=.31). The weighted prevalence of AVHD was highest in Central Americans (8.4%) and lowest in Mexicans (1.2%). Regurgitant lesions of moderate or greater severity were present in 2.4% of the population and stenotic lesions of moderate or greater severity in 0.2%. Compared with those without AVHD, individuals with AVHD were more likely to have health insurance coverage (59.6% vs 79.2%; P=.007) but similar income (P=.06) and educational status (P=.46). Univariate regression models revealed that regurgitant lesions were associated with lower body mass index whereas stenotic lesions were associated with higher body mass index. Conclusion: Our data provide the first population-based estimates of the prevalence of valvular heart disease in Hispanic/Latinos. Valvular heart disease is fairly common in the Hispanic/Latino population and may constitute an important public health problem.
UR - http://www.scopus.com/inward/record.url?scp=85068214095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068214095&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2018.12.035
DO - 10.1016/j.mayocp.2018.12.035
M3 - Article
C2 - 31279542
AN - SCOPUS:85068214095
SN - 0025-6196
VL - 94
SP - 1488
EP - 1498
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 8
ER -
